Find Federal Grants
Innovative Programs to Enhance Research Training (IPERT) (R25 Independent Clinical Trial Not Allowed)
National Institutes of Health · PAR-21-196
Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed)
National Institutes of Health · RFA-AR-21-016
Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjgrens Syndrome (UC2 Clinical Trial Optional)
National Institutes of Health · RFA-AR-21-015
Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)
National Institutes of Health · RFA-HD-22-010
National Institutes of Health · PA-21-201
National Institutes of Health · PA-21-200
National Institutes of Health · PA-21-199
NIDCD's Mentoring Networks to Enhance Clinician-Scientists' Participation in Research (R25 Clinical Trial Not Allowed)
National Institutes of Health · PAR-21-187
Zimbabwe USAID-Harare · 72061321RFA00008
Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health · RFA-AI-21-012
Strengthening animal health systems to enhance prevention, detection and response to emerging zoonotic diseases
Centers for Disease Control - NCEZID · CDC-RFA-CK21-2105
Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44)
National Institutes of Health · RFA-HG-21-008
Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial Not Allowed)
National Institutes of Health · RFA-HG-21-006
National Institutes of Health · RFA-AI-21-025
Multidisciplinary Treatment Approaches to End the HIV Epidemic (R01 Clinical Trial Optional)
National Institutes of Health · RFA-AI-21-024
Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial Not Allowed)
National Institutes of Health · RFA-HG-21-007
Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)
National Institutes of Health · RFA-AI-21-023
Mechanisms of HIV Resistance to Broadly Neutralizing Antibodies (bNAbs) (U01 Clinical Trial Not Allowed)
National Institutes of Health · RFA-AI-21-009
National Paralysis Resource Center
Administration for Community Living · HHS-2021-ACL-AOD-PRRC-0078
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
National Institutes of Health · PAR-21-162